TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06464055: A Phase I/II, Multicenter, Open-Label, Dose-Escalation and Extension Study of GQ1010(an Anti-Trop2 ADC) in Subjects With Advanced Solid Tumors

Sponsor: GeneQuantum Healthcare (Suzhou) Co., Ltd. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 260 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT06464055 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06464055 Rescue Dossier →